172 results on '"Canaani, Jonathan"'
Search Results
2. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis
3. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT
4. Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol
5. ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy
6. Evaluation of the clinical impact of bone marrow cultures in current medical practice
7. Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy
8. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
9. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
10. Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis
11. Emerging Therapies for the Myelodysplastic Syndromes
12. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell–Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia
13. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
14. A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity
15. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia
16. Management of AML Beyond “3 + 7” in 2019
17. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation
18. Prevention and treatment of relapse after stem cell transplantation with immunotherapy
19. Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
20. Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients.
21. Real-World Efficacy Outcomes of FLT3-ITDmut Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction
22. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation
23. Thiotepa‐based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched‐pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
24. Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies
25. Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study
26. Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia
27. Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group
28. Real-World Efficacy Outcomes of FLT3-ITD mut Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction.
29. FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation
30. Predictive Parameters for a Diagnostic Bone Marrow Biopsy Specimen in the Work-Up of Fever of Unknown Origin
31. Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years.
32. 32 - Non T–Cell Depleted Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
33. Heparanase expression increases throughout the endometrial hyperplasia–cancer sequence
34. Acute myeloid leukemia with 11q23/MLL rearrangement after ‘FCR’ regimen for chronic lymphocytic leukemia
35. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
36. Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy.
37. T-Wave Amplitude Is Related to Physical Fitness Status
38. Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
39. Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients
40. The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival
41. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease
42. Outcome of T‐cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
43. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
44. ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy
45. A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia.
46. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation
47. 58 - The Role of Cytogenetic Risk Stratification in FLT3 Mutated NPM1 Negative AML Patients Undergoing Allogeneic Stem Cell Transplantation (alloSCT) in Remission: A Study on Behalf of the ALWP of the EBMT
48. Two‐dimensional speckle‐tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
49. First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study
50. A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.